Introduction
Allergan (AGN) released the prospectus for its merger with AbbVie (ABBV) on September 17. Allergan shareholders will vote on the merger on October 14. AbbVie shareholders will not automatically receive this document because AbbVie is issuing less than 20% of its currently outstanding share count in the merger. This means that AbbVie shareholders will not get to vote. Nevertheless, I would highly recommend AbbVie shareholders download and read the prospectus. Following the merger, Allergan shareholders will receive $120.30 in cash and 0.866 shares of AbbVie for every Allergan share they